These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33186562)

  • 1. Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder.
    Tafseer S; Gupta R; Ahmad R; Jain S; Bhatia MS; Gupta LK
    Pharmacol Biochem Behav; 2021 Jan; 200():173073. PubMed ID: 33186562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Agomelatine and Fluoxetine on HAM-D Score, Serum Brain-Derived Neurotrophic Factor, and Tumor Necrosis Factor-α Level in Patients With Major Depressive Disorder With Severe Depression.
    Gupta K; Gupta R; Bhatia MS; Tripathi AK; Gupta LK
    J Clin Pharmacol; 2017 Dec; 57(12):1519-1526. PubMed ID: 28833192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression.
    Gupta R; Gupta K; Tripathi AK; Bhatia MS; Gupta LK
    Pharmacology; 2016; 97(3-4):184-8. PubMed ID: 26854819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study.
    Aydemir O; Deveci A; Taneli F
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):261-5. PubMed ID: 15694233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features.
    Patas K; Penninx BW; Bus BA; Vogelzangs N; Molendijk ML; Elzinga BM; Bosker FJ; Oude Voshaar RC
    Brain Behav Immun; 2014 Feb; 36():71-9. PubMed ID: 24140302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine.
    Ghosh R; Gupta R; Bhatia MS; Tripathi AK; Gupta LK
    Asian J Psychiatr; 2015 Dec; 18():37-41. PubMed ID: 26514447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression.
    Jamerson BD; Krishnan KR; Roberts J; Krishen A; Modell JG
    Psychopharmacol Bull; 2003; 37(2):67-78. PubMed ID: 14566216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations between brain-derived neurotrophic factor and clinical symptoms in medicated patients with major depression.
    Satomura E; Baba H; Nakano Y; Maeshima H; Suzuki T; Arai H
    J Affect Disord; 2011 Dec; 135(1-3):332-5. PubMed ID: 21774990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Val66Met polymorphism association with serum BDNF and inflammatory biomarkers in major depression.
    Caldieraro MA; McKee M; Leistner-Segal S; Vares EA; Kubaski F; Spanemberg L; Brusius-Facchin AC; Fleck MP; Mischoulon D
    World J Biol Psychiatry; 2018 Aug; 19(5):402-409. PubMed ID: 28656803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.
    Reimherr FW; Cunningham LA; Batey SR; Johnston JA; Ascher JA
    Clin Ther; 1998; 20(3):505-16. PubMed ID: 9663366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Brain-derived neurotrophic factor (BDNF): the severity and symptomatic dimensions of depression.
    Jevtović S; Karlović D; Mihaljević-Peleš A; Šerić V; Vrkić N; Jakšić N
    Psychiatr Danub; 2011 Dec; 23(4):363-9. PubMed ID: 22075737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants.
    Shimizu E; Hashimoto K; Okamura N; Koike K; Komatsu N; Kumakiri C; Nakazato M; Watanabe H; Shinoda N; Okada S; Iyo M
    Biol Psychiatry; 2003 Jul; 54(1):70-5. PubMed ID: 12842310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bupropion in the treatment of outpatients with asthma and major depressive disorder.
    Brown ES; Vornik LA; Khan DA; Rush AJ
    Int J Psychiatry Med; 2007; 37(1):23-8. PubMed ID: 17645195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features.
    Seo HJ; Lee BC; Seok JH; Jeon HJ; Paik JW; Kim W; Kwak KP; Han C; Lee KU; Pae CU
    Pharmacopsychiatry; 2013 Sep; 46(6):221-6. PubMed ID: 23963965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BDNF plasma levels variations in major depressed patients receiving duloxetine.
    Fornaro M; Escelsior A; Rocchi G; Conio B; Magioncalda P; Marozzi V; Presta A; Sterlini B; Contini P; Amore M; Fornaro P; Martino M
    Neurol Sci; 2015 May; 36(5):729-34. PubMed ID: 25501804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of last depressive episode may influence serum BDNF levels in remitted patients with major depression.
    Takebayashi N; Maeshima H; Baba H; Nakano Y; Satomura E; Kita Y; Namekawa Y; Nomoto H; Suzuki T; Arai H
    Depress Anxiety; 2012 Sep; 29(9):775-9. PubMed ID: 22447660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of milnacipran on brain‑derived neurotrophic factor and oxidative stress biomarkers in patients of major depressive disorder.
    Gupta R; Ghosh R; Bhatia MS; Tripathi AK; Gupta LK
    Acta Neurobiol Exp (Wars); 2023; 83(1):57-62. PubMed ID: 37078814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.